Farshad Homayouni Moghadam, Abolghasem Abbasi, Abbas Vakili-Zarch, Mehrdad Mansouri, Mojtaba Babaei-Zarch, Mohammad Hossein Nasr-Esfahani
Direct remyelinating effect of bone marrow mesenchymal stem cells in the rat model of spinal cord injury
Farshad Homayouni Moghadam1*, Abolghasem Abbasi2, Abbas Vakili-Zarch2, Mehrdad Mansouri2, Mojtaba Babaei-Zarch2, Mohammad Hossein Nasr-Esfahani1
1Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.2Neurobiomedical Research Center, Shahid Sadoughi Yazd University of Medical Sciences, Yazd, Iran.
Several studies have tried to evaluate the effects of stem cell therapy for spinal cord injury in animal models and human trials. Bone marrow mesenchymal stem cells are one of the safe and available candidate cells with established beneficial therapeutic effects for bone and cartilage repair. However, there are some doubts regarding their therapeutic efficacy for nervous system disorders. Bone marrow mesenchymal stem cells have been used in some clinical trials for spinal cord injury but their precise mechanism of action and also their safety has not been investigated. Available experimental reports do not provide sufficient and convincing evidence to persuade therapists to perform further clinical trials. In the present study we have used detailed staining methods to clearly show the entire structure of the injured spinal cord and the effects of bone marrow mesenchymal stem cells treatment on this tissue.Intrathecal injection of neutral red stained bone marrow mesenchymal stem cells were done in a rat model of spinal cord injury and the fate of the transplanted cells, immunologic responses in the host tissue, and tumor generation were assessed by using brightfield and fluorescence microscopy. Sensory-motor functions were also evaluated in the animals.Injected cells could migrate to the site of the injury and differentiate into oligodendrocytes and astrocytes. Immuno-histological assays showed no cells expressing CD2, CD3, CD15 and CD45 in host tissues, and sensory-motor assessments revealed that there were some partial improvements.Present study provides strong evidence that mesenchymal stem cell therapy is safe and could be helpful for the remyelination of injured nerve fibers in the acute phase of injury.
Mesenchymal stem cell, Oligodendrocyte, Spinal cord injury, Myelination, Differentiation, Stem cell therapy
Spinal cord injury (SCI) is followed by damage to the myelin sheath, axonal degeneration and death of the neurons[1]. Recently, mesenchymal stem cells (MSCs) have been considered to be partially useful for the treatment of SCI [1–3]. MSCs are multi-potential cells and therefore they can differentiate into several types of cells [4]. It has been reported that MSCs could differentiate toward different cell types like neurons, adipocytes, chondrocytes and osteoblasts in vitro, but their differentiation properties in vivo are not completely clear [4, 5]. There is a specific interest in them as a suitable source of stem cells because they are easily available from a patient’s bone marrow[6]. It is believed that MSCs could restore the damage to the spinal cord by reducing the damage size or replacing the destroyed cells [7–9]. Also, some researchers have proposed that stem cells can provide growth factors to increase the survival of the residual host cells following an injury [10]. Also, researchers have reported that transplantation of MSCs may have a therapeutic role because of their neural differentiation-inducing effects or by their direct shift to neuronal cells [11, 12]. Other studies have shown that MSCs promote axonal regeneration and attenuate apoptosis in a lesion site and support the injury recovery through their secreted exosomes [13]. Some reports have indicated that MSCs can protect sensory neurons from damage but not cortical neurons [14]. In addition, in some recent studies, it was suggested that bone marrow has a population of neural crest precursors or neuroectodermal progenitor cells, which can repair nerve defects by secreting specific growth factors [11] or by possible differentiation toward Schwann Cells[15]. Therefore, according to the findings from several laboratories, transplantation of MSCs in spinal cord injury can promote recovery in traumatic SCI.
Based on the reports mentioned above, a variety of functions are attributed to MSCs, however, to the best of our knowledge the exact fate of these cells and ultimate immunological responses of the host tissue following MSC transplantation are still not fully understood. This study aims to assess whether the implanted MSCs can induce the regeneration of the nerve fibers to enhance the recovery of sensory-motor function following transplantation into the injured spinal cord.
A total of 33 male Sprague-Dawley rats were used for this study: 5 for MSC isolation and 28 for laminectomy and inducing contusion-based spinal cord injury. The rats were 6–8 months old and weighed 300–350g. The animals were kept under standard conditions at 25ºC temperature and a 12-h light/dark cycle with humidity of 45%–55%. They were allowed free access to water and food. All experimental protocols on animals were approved by the Royan Institute Ethical Committee.
Five rats were euthanized under deep anesthesia and their femurs and tibias were removed to collect bone marrow. The remaining animals were divided randomly into four groups, with 7 rats in each group. The groups were 1) laminectomy or sham lesion (S), 2) laminectomy + trauma + phosphate-buffered saline (PBS) or vehicle-treated (V), 3) laminectomy + trauma + MSCs or MSC-treated (MSC), 4) laminectomy + trauma + induced MSCs or iMSC-treated (iMSC). All treated rats were sacrificed after behavioral tests and their spinal cords were removed for histological assessments.
Under sterile conditions, the femurs and tibias were removed and transferred to a 50mL conical tube containing cold PBS solution. Under the laminar hood their bone marrowwas flushed with Dulbecco’s modified eagle medium-low glucosesupplemented with 2% penicillin/streptomycin. Bone marrow samples were centrifuged for 5 min at 300×g to obtain a cell pellet. After the removal of the supernatant, the cells were re-suspended in 25 mL of MSCs-medium containing Dulbecco’s modified eagle medium-low glucose supplemented with 10% fetal bovine serum, 1% non-essential amino acids 1% GlutaMax, and 1% penicillin/streptomycin. Cells were then plated and cultured in T-150cm2culture flasks at 37°C in a humidified atmosphere with 5% CO2. The non-adherent cells were removed by changing the culture medium every three days after seeding. The cells were detached using 0.25% trypsin solution and re-plated into culture flasks at a 1:3 split ratio. All cell culture media, reagents, and sera were purchased from Thermo Fisher Scientific, USA.
Priming of the MSCs toward neural lineage cells was performed based on previous reports by some molecular modifications; briefly, MSCs were cultivated on fibronectin-coated plates in serum-free neuro-basal medium containing basic fibroblast growth factor, epidermal growth factor (both 10 ng/mL), 2-mercaptoethanol 50µM and N2supplements for 2 weeks [16]. Then the cells were re-suspended by trypsin treatment and collected by centrifugation. Next, before transplantation, the cells were stained with neutral red (NR) to make them traceable in the animal body. NR is a safe fluorescent dye suitable for live-cell staining, therefore it is possible to detect stained cells under both optical and fluorescent microscopes. For this purpose, NR staining solution 5mg/mL was prepared by dissolving it in PBS. Then the cells were suspended in PBS and incubated for 10 minutes in the presence of NR by adding 10µl of NR-solution to each ml of cell suspension. Then the cells were centrifuged and washed twice with PBS and re-suspended in PBS for transplantation.
For the preparation of non-induced MSCs, cells were cultured in MSC-medium to become 90% confluent, then they were trypsinized and NR staining was performed before transplantation.
Animals were anesthetized by intraperitoneal injection of ketamine (80mg/kg) and xylazine (10mg/kg) cocktail. Laminectomy was performed at the T12 (12th thoracic vertebra) level of the vertebral column, then a contusion injury was induced by dropping a 10g weight from a height of 10cm on to the exposed cord, the wound was washed, and damage of the cord was observed under a stereomicroscope [17]. After injury induction, the surgical incision site was sutured. All animals received intramuscular injections of antibiotics (penicillin (4mg/kg) & gentamicin (5mg/kg)) once a day for one week. Stem cell injections were performed eight days after induction of injury. Injected cells were in their 4th passage number. Animals were anesthetized and 4*105cells/5μL of MSCs or iMSCs were injected intrathecally at lumbar vertebrae L3–5 via Hamilton syringe with a 30-gauge needle. Cells were injected for a 5-minute period and the needle was removed 10 minutes after injection to prevent leakage [18].
Basso-Beattie-Bresnahan (BBB) and combined behavioral score (CBS) tests were performed weekly for 4 weeks post-injury to evaluate the sensory and motor functions of the animals. The BBB test was used to score the recovery of locomotor skills in the experimental and control animals. In this test, a normal animal receives a score of twenty-one, while a complete spinal cord injured animal receives a zero [19]. The CBS test was used for the evaluation of the overall hind limb sensory and motor functions. CBS is a set of evaluations with multiple sections including motor score, foot placing, toe spread, pain, pressure withdrawal reflex, inclined plane, and righting reflex [20]. Its rating score is from zero to one hundred, zero for a normal and one hundred for a completely paralyzed animal.
At the end of 4 weeks, animals were deeply anesthetized with ketamine (100mg/kg) and xylazine (15mg/kg) and then euthanized by cervical dislocation, following direct fixative perfusion (paraformaldehyde 4%) through the circulatory system. Their spinal cords were removed surgically and incubated in 4% paraformaldehyde for 2 days. The collected tissues were dehydrated in graded ethanol, embedded in melted paraffin, and were sectioned.Several 10µm thick sections were prepared using a microtome. Next, the sections were de-paraffinized and rehydrated through washes in serially diluted ethanol (100%–70%). Immunohistochemical staining was performed using primary antibodies to CD2 (Santa Cruz, mouse monoclonal IgG1, sc-18907), CD3 (Santa Cruz, mouse monoclonal IgG1, sc-20047), CD15 (sc-19648), CD45 (sc-1178), and myelin basic protein (Chemicon; AB5864), and the secondary antibodies were m-IgGκ BP-HRP (sc-516102) for CD2,3,15,45 primary antibodies and FITC-conjugated goat anti-rabbit IgG (Sigma, F1262) for myelin basic protein antibody. Hematoxylin staining was used as a counterstaining in DAB (3, 3′-Diaminobenzidine) to trace the location of the transplanted cells.
In immunofluorescence staining, the nuclei were counterstained using DAPI (Sigma, D5964). To trace the transplanted cells (NR stained) photos were captured from them before immunostaining. Tissue staining was performed using the standard protocol, briefly, tissue sections were pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 min, then after several washes, they were incubated with primary antibody overnight at 4°C and then washed several times and incubated with the specified secondary antibody for 2-hours at room temperature. For horseradish peroxidase-conjugated secondary antibodies at the end of incubation sections were incubated with 0.05% 3,3'-diaminobenzidine - 0.015% H2O2in 0.01 molar PBS, pH 7.2 solution.
One-way analysis of variance, followed by Tukey’s post hoc t-tests were performed to examine the significant differences between the groups.-value < 0.05 was considered statistically significant. All data are presented as mean±standard error of mean.
As it was expected, hind limb paraplegia was observed in the SCI group animals after induction of contusion spinal cord injury (Figure 1A and Figure 1B). BBB test recordings at one week after injury (one day before cell therapy) signified that in the experimental SCI groups (SCI-vehicle, SCI-MSC and SCI-iMSC) the mean scores were significantly lower in BBB test and higher in CBS test compared to the sham-lesion group (<0.0001). Although this evident and significant difference emerged slowly over time in the following weeks, it remained tremendously significant until the last week of the study (<0.0001).
After cell therapy, a gradual sensory-motor recovery was visible in SCI animals and it was slightly better in the SCI-MSC and SCI-iMSC groups, as in the fourth week this dominance reached the point that was significantly different from the SCI-vehicle groupv(<0.05)(Figure 1A and Figure 1B).
General histological staining using hematoxylin showed that the transplanted cells were traceable in the injury site and their morphology was very similar to astrocytes and oligodendrocytes. We found NR-stained cells in different areas of the white and gray matter of the spinal cord and particularly in the lesion site. Our findings in this part demonstrate that transplanted cells are able to generate different cells morphologically.

Figure 1 Results of the sensory-motor function tests. A, BBB test for evaluating motor function; B, CBS test for sensory-motor function assessment. Test acquisitions started one week after SCI induction and were performed weekly for four weeks. Cell injection was performed eight days after SCI induction, one day after the acquisition of the first test ($$$$compared to SCI animals:<0.0001;*compared to SCI-vehicle:<0.05). BBB, Basso-Beattie-Bresnahan; CBS, Combined Behavioral Score; SCI, spinal cord injury; MSCs, mesenchymal stem cells; iMSC, induced mesenchymal stem cell.
Figure 2 Immunohistochemical staining against myelin basic protein. Myelin basic protein is shown in green, nuclei of the host cells are in blue as stained with 4',6-diamidino-2-phenylindole and the injected cells have orange color (mix of red (neutral red) and blue (4',6-diamidino-2-phenylindole)). As shown here the transplanted cells could generate functional oligodendrocytes at the site of injury. MSCs, mesenchymal stem cells; iMSC, induced mesenchymal stem cell.
Immunostaining assays against myelin basic protein (Figure2) showed that these transplanted NR positive cells in the white matter of the spinal cord were oligodendrocytes, as in the Hematoxylin staining assays their protuberances and myelin neurokeratin were recognizable, as shown in Figure 3. Although the number of NR positive cells which were differentiated into oligodendrocytes was not enormous, our findings in this section showed that mesenchymal stem cells have this ability to generate oligodendrocytes and are capable to effectively contribute to repair nerve damagesdespite the fact that they may need to be injected in several times.
Staining against CD2 (cluster of differentiation 2, found on the surface of T cells and natural killer cells), CD3 (cluster of differentiation 3, a T cell co-receptor involving in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells)), CD15 (cluster of differentiation 15, found on neutrophils) and CD45 (cluster of differentiation 45, leucocyte common antigen) (Figure 4), showed that there were not any inflammatory or immunological responses such as immune cell activation or lymphocyte infiltration following cell transplantation in the host tissue. In addition, there were no gliosis and tumor-like structures in the tissue sections.
There are several reports regarding the efficacy of MSC therapy for SCI in animal models and some clinical trials in humans [22, 23]. Scientists have proposed several mechanisms of action for MSCs in improving the damages in SCI, such as regeneration and remyelination of damaged nerves, reduction in astrocyte growth in the injury site, stimulating nerve growth factor secretion, and reduction of inflammation [24–27]. Based on all of these reports the final fate of the transplanted cells is not clearly demonstrated yet [24]. Most of the prior studies have claimed that MSCs can decrease inflammatory responses in the site of injury or improve nerve regeneration or remyelination by secreting growth factors but not by direct differentiation toward neuronal cells[24].
Regarding the recent reports suggesting the existence of a population of neural crest precursor cells in BMMSCs we performed this study to evaluate their possible neuro-differentiation, and also the safety of these cells for transplantation in the nervous system [15].Our findings showed that the injected MSCs are safe for the nervous system and there was no immune response or tumor formation in the host tissue. Interestingly, MSCs successfully migrated to both gray and white matters and generated astrocytes in the gray matter and oligodendrocytes in the white matter. In the case of neuronal differentiation our histological assessments showed that MSCs were not able to fully generate new neurons in the spinal cord. Both types of injected cells in this study (MSCs and iMSCs) exerted some improvements in sensory and motor functions as they showed migration to the injury site. According to our behavioral assessments, it was shown that stem cell therapy was effective in reducing motor and sensory defects in the treated animals. Due to the presented data, we state that MSCs may generate oligodendrocytes in the site of injury and these cells contribute to the remyelination process, as we found them in the white matter.

Figure 3 Tracing the transplanted NR-stained MSCs in the spinal cord of the experimental rats. A and B are from MSC-treated groups, B is the magnified image of A. These two images were captured from longitudinal sections of the spinal cord without any staining to trace the implanted cells (cells with red cytoplasm were stained with NR before injection). C and D are from iMSC-injected group in longitudinal sections. The injected cells were NR-stained and after injection and staining with Hematoxylin acquired a dark brown color, as they are shown by short arrows in D. E and F show images in higher magnification from the MSC-treated group. In E the transplanted cells have a dark brown color and the cells of the host tissue have a pink color. There are two kinds of non-neuronal stained nuclei in this image, some are marked with a 4-point star and some with a 5-point star. Oligodendrocytes have dense nuclei, so in this image, they are stained darker (dark pink or dark brown, marked by 5-point stars) and astrocytes have large non dense nuclei (light pink and brown, marked by 4-pont star). This photo indicates that MSCs may differentiate into astrocytes and oligodendrocytes after transplantation. Image F was captured from white matter and neurokeratin is marked by the arrows.As shown, some implanted cells with brown nuclei are present in the white matter. G, H, and I are from the iMSC-injected group, which shows the differentiation of the implanted cells toward oligodendrocytes with their myelin neurokeratin (brown cells). NR, neutral red; MSCs, mesenchymal stem cells; iMSC, induced mesenchymal stem cell.
Figure 4 Horizontal sections of the spinal cords from all groups were stained against CD2, CD3, CD15 and CD45, specific markers for inflammatory cells. Sample positive control tissues are shown on the left side. These stainings showed that there were no inflammatory or immunologic responses following cell transplantation in the host spinal cord tissue. SCI, spinal cord injury; MSC, mesenchymal stem cell; iMSC, induced mesenchymal stem cell.
In our study, we used a simple method of staining with neutral red to trace the injected cells in the host body[28]. By this method, without using any genetic manipulation, we traced the cells in the tissue and by studying their morphology their possible role in healing was predicted. Enhanced green fluorescent protein has been widely used to trace transplanted cells, but there is evidence that enhanced green fluorescent protein may promote host tissue immune responses against the transplanted cells and therefore host body defense system can eliminate them as it is not a natural protein of the mammalian system [29].
In the case of tumorigenesis or arousing inflammatory responses we did not find any signs of these post-transplantation issues in the host tissue.
According to our findings with the MSCs that were injected one week after induction of injury in the spinal cord, we propose that stem cell therapy in the acute phase of SCI could be more effective since at this stage migration could be higher and gliosis is lower. In addition, the possibility of saving the damaged axons by direct MSC-remyelination process in this phase may be higher.
1. Rodriguez-Barrera R, Flores-Romero A, Buzoianu-Anguiano V, et al. Use of a combination strategy to improve morphological and functional recovery in rats with chronic spinal cord injury.. 2020;11:189. Available: 10.3389/fneur.2020.00189; https:/doi.org/10. 3389/fneur.2020.00189
2. Mukhamedshina Y, Shulman I, Ogurcov S, et al. Mesenchymal stem cell therapy for spinal cord contusion: acomparative study on small and large animal models.. 2019;9(12):811. Available: 10.3390/biom9120811; https://dx.doi. org/10.3390/biom9120811
3. Bydon M, Dietz AB, Goncalves S, et al. CELLTOP clinical trial: first report from a phase 1 trial of autologous adipose tissue-derived mesenchymal stem cells in the treatment of paralysis due to traumatic spinal cord injury.. 2020;95(2):406–414. Available: 10.1016/j.mayocp.2019.10.008; https:/doi.org/ 10.1016/j.mayocp.2019.10.008
4. Yang YJ, Li XL, Xue Y, et al. Bone marrow cells differentiation into organ cells using stem cell therapy.. 2016;20(13):2899–2907.Available: 10.1634/stemcells. 20-4-279; 10.1634/stemcells. 20-4-279
5. Tobin MK, Stephen TKL, Lopez KL, et al. Activated mesenchymal stem cells induce recovery following stroke via regulation of inflammation and oligodendrogenesis.. 2020;9(7):e013583. Available: 10.1161/JA HA.119.013583; https:/doi.org/10.1161/JAHA. 119.013583
6. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders--time for clinical translation?. 2010;120(1):29–40. Available: 10.1172/JCI40543; https:/doi.org/ 10.1172/JCI40543
7. Xu C, Fu F, Li X, Zhang S. Mesenchymal stem cells maintain the microenvironment of central nervous system by regulating the polarization of macrophages/microglia after traumatic brain injury.. 2017;127(12):1124–1135. Available:10.1080/00207454.2017.1325884; https: //dx.doi.org/10.1080/00207454.2017.1325884
8. Park SI, Lim JY, Jeong CH, et al. Human umbilical cord blood-derived mesenchymal stem cell therapy promotes functional recovery of contused rat spinal cord through enhancement of endogenous cell proliferation and oligogenesis.. 2012;2012:362473. Available: 10.1155/2012/362473; https:/doi.org/10.1155/ 2012/362473
9. Chen HX, Liang FC, Gu P, et al. Exosomes derived from mesenchymal stem cells repair a Parkinson’s disease model by inducing autophagy.. 2020;11(4):288. Available: 10.1038/s41419-020-2473-5; https:/doi.org/10. 1038/s41419-020-2473-5
10. Petrenko Y, Vackova I, Kekulova K, et al. A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. 2020;10(1):4290. Available: 10.1038/s41598-020- 61167-z; https:/doi.org/10.1038/s41598-020- 61167-z
11. Shi H, Li X, Yang J, et al. Bone marrow-derived neural crest precursors improve nerve defect repair partially through secreted trophic factors.. 2019;10(1):397. Available: 10.1186/s13287-019-1517-1; https:/doi.org/10. 1186/s13287-019-1517-1
12. Zhan J, Li X, Luo D, et al. Polydatin promotes the neuronal differentiation of bone marrow mesenchymal stem cells in vitro and in vivo: involvement of Nrf2 signalling pathway.. 2020 May;24(9):5317–5329. Available: 10.1111/jcmm.15187; https:/doi.org/10.1111/ jcmm.15187
13. Luo Y, Xu T, Liu W, et al. Exosomes derived from GIT1-overexpressing bone marrow mesenchymal stem cells promote traumatic spinal cord injury recovery in a rat model.. 2021;131(2):170–182. Available: 10.1080/002074 54.2020.1734598; https:/doi.org/10.1080/0020 7454.2020.1734598
14. Monfrini M, Ravasi M, Maggioni D, et al. Comparing the different response of PNS and CNS injured neurons to mesenchymal stem cell treatment.. 2018;86:16–24. Available: 10.1016/j.mcn.2017.11.004; https://dx. doi.org/10.1016/j.mcn.2017.11.004
15. Cai S, Tsui YP, Tam KW, et al. Directed differentiation of human bone marrow stromal cells to fate-committed schwann cells.. 2017;9(4):1097–1108. Available: 10.101 6/j.stemcr.2017.08.004; https:/doi.org/10.101 6/j.stemcr.2017.08.004
16. Balasubramanian S, Thej C, Venugopal P, et al. Higher propensity of Wharton’s jelly derived mesenchymal stromal cells towards neuronal lineage in comparison to those derived from adipose and bone marrow.. 2013;37(5):507–515. Available: 10.1002/cbin.10056; https:/doi.org/10.1002/cbin.10056
17. Tian W, Han XG, Liu YJ, et al. Intrathecal epigallocatechin gallate treatment improves functional recovery after spinal cord injury by upregulating the expression of BDNF and GDNF.. 2013;38(4):772–779. Available: 10.1007/s11064-013-0976-5; https:/doi.org/10.1007/s11064-013-0976-5
18. Paul C, Samdani AF, Betz RR, Fischer I, Neuhuber B. Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods.. 2009;34(4):328–334. Available:10.1097/BRS.0b013e31819403ce; https: //dx.doi.org/10.1097/BRS.0b013e31819403ce
19. Guo J, Cao G, Yang G, et al. Transplantation of activated olfactory ensheathing cells by curcumin strengthens regeneration and recovery of function after spinal cord injury in rats.. 2020;22(6):301–312. Available: 10.1016/j.jcyt.20 20.03.002; https:/doi.org/10.1016/j.jcyt.2020. 03.002
20. Wu J, Pajoohesh-Ganji A, Stoica BA, Dinizo M, Guanciale K, Faden AI. Delayed expression of cell cycle proteins contributes to astroglial scar formation and chronic inflammation after rat spinal cord contusion.. 2012;9:169. Available: 10.1186/1742-2094-9-169; https:/doi.org/10.1186/1742-2094-9-169
21. Pannese E.. 2nd ed. Springer International Publishing Switzerland;2015.
22. Romanelli P, Bieler L, Scharler C, et al. Extracellular vesicles can deliver anti-inflammatory and anti-scarring activities of mesenchymal stromal cells after spinal cord injury.. 2019;10:1225. Available: 10.33 89/fneur.2019.01225; https:/doi.org/10.3389/ fneur.2019.01225
23. Deng WS, Ma K, Liang B, et al. Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury.. 2020;15(9):1686–1700. Available: 10.4103/ 1673-5374.276340; https:/doi.org/10.4103/16 73-5374.276340
24. Dalamagkas K, Tsintou M, Seifalian A, Seifalian AM. Translational regenerative therapies for chronic spinal cord injury.. 2018;19(6):1776. Available: 10.3390/ijms190 61776; https:/doi.org/10.3390/ijms19061776
25. Vaquero J, Zurita M, Rico MA, et al. Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury.. 2017;19(3):349–359. Available:10.1 016/j.jcyt.2016.12.002;https:/doi.org/10.1016/ j.jcyt.2016.12.002
26. Xiao Z, Tang F, Zhao Y, et al. Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with neuroRegen scaffolds and mesenchymal stem cells.. 2018;27(6):907–915. Available: 10.1177/096368 9718766279; https:/doi.org/10.1177/096368 9718766279
27. Tsintou M, Dalamagkas K, Makris N. Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans.. 2020;15(3):425–437. Available: 10.4103/1673-53 74.266048; https:/doi.org/10.4103/1673-5374. 266048
28. Gray DW, Millard PR, McShane P, Morris PJ. The use of the dye neutral red as a specific, non-toxic, intra-vital stain of islets of Langerhans.. 1983;64(5):553–558.
29. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: implications for gene therapy.. 1999;6(7):1305–1312. Available: 10.1038/sj.gt.3300951; https://dx.doi. org/10.1038/sj.gt.3300951
thanks David J. Mishelevich, Jose Ignacio Nolazcothe and the other anonymous reviewer(s) for the contribution to the peer review of this paper.
:
SCI, spinal cord injury; MSCs, mesenchymal stem cells; BMMSC, bone marrow mesenchymal stem cell; NR, neutral red; BBB, Basso-Beattie-Bresnahan; CBS, Combined Behavioral Score; PBS, phosphate-buffered saline.
:
The authors declare that they have no conflict of interest.
:
We would like to acknowledge the support of the stem cell department of Royan Institute.
:
Moghadam FH, Abbasi A, Vakili-Zarch A, Mansouri M, Babaei-Zarch M,Nasr-Esfahani MH. Direct remyelinating effect of bone marrow mesenchymal stem cells in the rat model of spinal cord injury.. 2021;4(3):18. doi: 10.53388/life2021-0426-102.
:Shan-Shan Lin.
:26 April 2021,
10 June 2021,
:07 July 2021
© 2021 By Authors. Published by TMR Publishing Group Limited. This is an open access article under the CC-BY license (http://creativecommons.org/licenses/BY/4.0/).
Farshad Homayouni Moghadam. Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, Royan Ave., Isfahan, Iran; E-mail:homayouni@royan-rc.ac.ir.